Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MHB118C in Advanced Solid Tumors
NCT07045454Phase 1Recruiting
- Sponsor
- Minghui Pharmaceutical, Inc.
- Start
- Mar 2025
- Primary completion
- Mar 2029
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of MHB118C in solid tumor (advanced stage), sponsored by Minghui Pharmaceutical, Inc. Primary endpoints: Dose-Limiting Toxicity at day 21 and Maximum Tolerated Dose at day 21. Started Mar 2025; status: recruiting.
02
Drugs
MHB118C
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07045454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07045454.